Harnessing the natural cellular process of autophagy to design powerful new medicines


Casma Therapeutics is harnessing the natural cellular process of autophagy to open vast new target areas for drug discovery and development. Casma uses several approaches to intervene at strategic points throughout the autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens. By boosting autophagy, Casma expects to be able to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, among other indications.


Year Invested: 2018
Location: Cambridge, MA
Visit: www.casmatx.com/

Recent News

December 12, 2018
Casma Therapeutics Strengthens Leadership Team with Appointment of Chief Operating Officer, Vice President of People & Culture

December 6, 2018
Casma Therapeutics Licenses Technology to Advance Autophagy-Based Drug Discovery

September 11, 2018
Casma Therapeutics Announces Partnership with Fondazione Telethon, Founder of the Telethon Institute of Genetics and Medicine (TIGEM)

Read More News

Associated Team Members

Cary Pfeffer, M.D.
Partner

Robert Tepper, M.D.
Partner